Pancreatic Cancer

The goal of cancer immunotherapy is to improve the body’s natural ability to find and destroy cancer cells. Successful immunotherapeutic approaches stimulate the natural defenses of the immune system and provide new ways to attack cancer. This is possible with comprehensive interventions that include cell therapy / immuno-pharmacological therapy in combination with nutritional, endocrine measures and supplements.

T-cell Modulators are peptide chains composed of tens of amino acids that appear to store all the experience of the immune system. The great intellectual leap to understand is that T-cell Modulators do not transfer antibodies nor create them directly, but its function is to educate, and teach the immune cells to recognize specific antigens that could happen to them unnoticed i.e. Pancreatic malignant cells.

T-cell Modulators do not cure anything but work to make a “smarter” immune system so that it is the body itself eliminating disease. They are therefore vital in developing the strategies of the immune system against cancer.

T-cell Modulators contains several immunoactive components that have been shown to act synergistically in raising Dendritic and NK function and also effective as adjuvant therapy in Pancreatic cancer treatments, elevating dendritic and NK function as much as 250%.

Hyperthermia involves the use of heat to directly treat a tumor or increase the vulnerability of cancer cells to other forms of treatment, such as immunotherapy, B17, vitamin C, chemotherapy or radiotherapy.

Mistletoe helps fight tumor-induced immune suppression. Natural killer cells (NK) are a type of white blood cell that looks for and destroys Pancreatic cancer cells. Research has shown that NK cells can spontaneously recognize and kill a variety of Pancreatic cancer cells.

Mistletoe has been called a “biological response modifier” due to its ability to improve various aspects of immune function. Studies show that it activates natural killer cells, T cells, macrophages and monocytes. A special proprietary form of liposomal mistletoe created with nanotechnology has been created for use in our Pancreatic cancer treatment approach.

Glutathione is the most important antioxidant produced by your body and a master detoxifier of every cell in your body. It prevents cellular damage caused by free radicals and peroxides. Glutathione metabolism is able to play both protective and pathogenic roles. It is crucial in the removal and detoxification of carcinogens, and alterations in this pathway can have a profound effect on cell survival. However, by conferring resistance to a number of chemotherapeutic drugs, elevated levels of glutathione in tumor cells are able to protect such cells.

A typical diet, characterized by dependence on animal products, refined carbohydrates and unhealthy fats such as processed vegetable oils, can promote an inflammatory environment in the body. A pro-inflammatory diet has been associated with an increased risk of Pancreatic cancer and an increased risk of death from Pancreatic cancer.

We custom-make a diet targeted to enhance the immune system’s ability to heal and provide our patients with the right nutrition for their current and long-term needs.

Patients with higher vitamin D levels were significantly less likely to die from the disease (Mondul 2016). In another study, short-term supplementation with high-dose vitamin D for three to eight weeks lowered PSA levels (Wagner 2013). Pancreatic cancer patients have a high prevalence of vitamin D deficiency indicating the need for appropriate supplementation (Fisher 2009). Vitamin D3 has multiple protective effects against pancreatic cancer including anti-angiogenic, anti-metastatic, anti-inflammatory, and immunomodulatory effects (Hung Pham 2011; Bulathsinghala 2010).

Healthy pancreas cells accumulate zinc to accomplish their normal cellular functions. In contrast, prostate cancer cells have depleted zinc stores, which makes them less susceptible to cell death.

Melatonin, a hormone best known for its role in regulating sleep, is also emerging as a promising anti-cancer agent. Evidence to date has shown that melatonin can interfere with cancer initiation, progression, and metastasis. In a clinical study in which melatonin plus low-dose interleukin-2 (IL-2) was used to treat pancreatic cancer patients with a life expectancy of less than 6 months, a complete response was achieved in one pancreatic cancer patient, and a partial response in three others.

Immunotherapy with melatonin and IL-2 was a well-tolerated and effective therapy for almost all advanced cancer patients with solid tumors, including those who did not respond to IL-2 alone or to chemotherapy (Lissoni 1995).